Stoke Therapeutics

STOKE THERAPEUTICS INC

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

STOK

Biotech

Large Cap

News

Health Care

Contracts

General

BIIB

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

Biogen Strengthens Pipeline With Stoke Therapeutic&#39;s Dravet Syndrome Candidate Via Multi-Million Dollar Deal

movers image

Intraday Update

Markets

Movers

Trading Ideas

BTDR

CCRN

HSAI

JBLU

MRVL

MVST

NVTS

PATH

POWL

PSTG

ROKU

SOUN

ZETA

Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday

Wall Street, US stocks

Earnings

Equities

Pre-Market Outlook

EPAC

OMIC

XAIR

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday

Stoke Therapeutics Inc

Press Releases

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Stoke Therapeutics Announces CEO Transition

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

PRAX

Absci

Abivax

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Altimmune

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Celcuity

Erasca

Heron Therapeutics

Keros Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

Precigen

PureTech Health plc - American Depositary Shares

PureTech Health

Regenxbio

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sana Biotechnology

Savara

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Tourmaline Bio

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Upstream Bio

Verve Therapeutics

Verastem

HC Wainwright & Co.

Chardan Capital

Needham

Wedbush

Canaccord Genuity

Comments

Stoke Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga